Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.67 |
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.63 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.53 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3870152 | 0.98 | HDAC1 (0.65) | HDAC1HDAC8HDAC6HRH3CYP2D6 | |
| SCHEMBL27854081 | 0.98 | HRH3 (0.67) | HDAC1HDAC8HDAC6HRH3CYP2D6 | |
| SCHEMBL2741682 | 0.98 | HRH3 (0.67) | HDAC1HDAC8HDAC6HRH3CYP2D6 | |
| SCHEMBL2986364 | 0.98 | HRH3 (0.67) | HDAC1HDAC8HDAC6HRH3CYP2D6 | |
| Hydrochloric Acid SCHEMBL10374042 | 0.96 | HRH3 (0.64) | HDAC1HDAC8HDAC6HRH3CYP2D6 | |
| Hydrochloric Acid SCHEMBL228646 | 0.96 | HRH3 (0.64) | HDAC1HDAC8HDAC6HRH3CYP2D6 | |
| Hydrochloric Acid SCHEMBL7654075 | 0.96 | HRH3 (0.64) | HDAC1HDAC8HDAC6HRH3CYP2D6 | |
| SCHEMBL20828408 | 0.96 | HDAC1 (0.62) | HDAC1HDAC8HDAC6HRH3CYP2D6 | |
| SCHEMBL10074441 | 0.92 | HDAC1 (0.62) | HDAC1HDAC8HDAC6HRH3CYP2D6 | |
| SCHEMBL27519383 | 0.87 | HDAC4 (0.71) | HDAC1CYP2D6ALDH1A1KDM4EHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4305940-A | Benzamides with local anaesthetic and antiarrhythmic activity, salts, and method of preparation thereof and pharmaceutical compositions therefrom | B.B.R. BOEHRINGER BIOCHEMIA ROBIN S.P.A. (IT) | 1981-12-15 | — | — | US | claimed |
| EP-3623372-B1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH INC (US) | 2026-02-04 | — | — | EP | disclosed |
| US-12018030-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| CN-118005638-A | Pyrazolo [3,4-d ] pyrimidine structure-containing compound, and preparation method and application thereof | 西安新通药物研究股份有限公司 | 2024-05-10 | — | — | CN | disclosed |
| EP-4108666-A1 | MULTI-TARGET TYROSINE KINASE INHIBITOR | Shenzhen Neptunus Pharmaceutical Research Institute Co., Ltd. (CN) | 2022-12-28 | — | — | EP | disclosed |
| US-20210332052-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2021-10-28 | — | — | US | disclosed |
| US-20210332052-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2021-10-28 | — | — | US | disclosed |
| US-10934299-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10934299-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| EP-3623372-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | Forma Therapeutics, Inc. (US) | 2020-03-18 | — | — | EP | disclosed |
| WO-2013070657-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-05-16 | — | — | WO | disclosed |
| US-20120238565-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS | MERCK SERONO SA (CH) | 2012-09-20 | — | — | US | disclosed |
| US-8263595-B2 | Triazolopyridine compounds and their use as ask inhibitors | MERCK SERONO SA (CH) | 2012-09-11 | — | — | US | disclosed |
| WO-2012106343-A2 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-08-09 | — | — | WO | disclosed |
| US-20100197681-A1 | Triazolopyridine Compounds and Their Use as Ask Inhibitors | MERCK SERONO SA (CH) | 2010-08-05 | — | — | US | disclosed |
| EP-2181112-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS | Merck Serono S.A. (CH) | 2010-05-05 | — | — | EP | disclosed |
| US-7601868-B2 | Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-13 | — | — | US | disclosed |
| US-7601868-B2 | Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-13 | — | — | US | disclosed |
| US-20090247470-A1 | PHENYLALANINE DIPEPTIDE DERIVATIVES, COMPOSITIONS AND USE THEREOF | The Key Lab. Of Chemistry for Natural Products of Guizhou Province and Chinese Acad. of Sciences (CN) | 2009-10-01 | — | — | US | disclosed |
| WO-2009027283-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS | MERCK SERONO S.A. (CH) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018030-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, UBXN1 | HDAC1 866/4885HDAC8 1646/4885HDAC6 1165/4885 |
| US-20090247470-A1 | PHENYLALANINE DIPEPTIDE DERIVATIVES, COMPOSITIONS AND USE THEREOF | DNPEP, PEPD, VIP | HDAC1 4690/4885HDAC8 4718/4885HDAC6 4077/4885 |
| US-20100197681-A1 | Triazolopyridine Compounds and Their Use as Ask Inhibitors | MAP3K5, MAPKAPK5, MAP3K9 | HDAC1 1757/4885HDAC8 1273/4885HDAC6 1307/4885 |
| US-20210332052-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, UBXN1 | HDAC1 866/4885HDAC8 1646/4885HDAC6 1165/4885 |
| US-20120238565-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS | MAP3K5, MAPKAPK5, MAP3K9 | HDAC1 1757/4885HDAC8 1273/4885HDAC6 1307/4885 |
| US-10934299-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, UBXN1 | HDAC1 866/4885HDAC8 1646/4885HDAC6 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.